• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Radial versus femoral access in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: A propensity-matched analysis from real-world data of the K-ACTIVE registry
CONCLUSION: In STEMI patients undergoing primary PCI, in comparison to femoral access, radial access reduced composite events in the entire population and the matched population, through a reduction in MACE and BARC 3 or 5 bleeding.PMID:36163313 | DOI:10.1016/j.jjcc.2022.09.001
Source: Journal of Cardiology - September 26, 2022 Category: Cardiology Authors: Hiroyoshi Mori Kaoru Sakurai Yuji Ikari Kazuki Fukui Atsuo Maeda Yoshihiro Akashi Junya Ako Toshiaki Ebina Kouichi Tamura Atsuo Namiki Ichiro Michishita Kazuo Kimura Hiroshi Suzuki Source Type: research

Clinical characteristics and outcomes of Japanese atrial fibrillation patients with poor medication adherence: A sub-analysis of the GENERAL study
CONCLUSIONS: Poor anticoagulant adherence, as measured by PDC <80 %, was associated with higher incidence of stroke or systemic embolism and major bleeding in the GENERAL study.PMID:35985869 | DOI:10.1016/j.jjcc.2022.07.022
Source: Journal of Cardiology - August 19, 2022 Category: Cardiology Authors: Masaharu Akao Hikari Tsuji Kengo Kusano Kunihiko Matsui Shinya Hiramitsu Yutaka Hatori Hironori Odakura Hisao Ogawa Source Type: research

Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2
CONCLUSIONS: Dabigatran continues to be safe and well tolerated in patients with NVAF for stroke and systemic embolism prevention and continues to be prescribed appropriately. Treatment outcomes have not changed since the availability of idarucizumab. Since the J-Dabi1 study, treatment guidelines for anticoagulation use in NVAF have been updated based on emerging clinical evidence, accounting for differences in patient characteristics, and making dabigatran a preference for distinct patient populations.PMID:35717283 | DOI:10.1016/j.jjcc.2022.04.007
Source: Journal of Cardiology - June 18, 2022 Category: Cardiology Authors: Takeshi Yamashita Shinichiro Uchiyama Hirotsugu Atarashi Ken Okumura Yukihiro Koretsune Masahiro Yasaka Junichi Wakayama Taku Fukaya Hiroshi Inoue J-Dabigatran Surveillance Investigators Source Type: research

Trends of anticoagulant use and outcomes of patients with non-valvular atrial fibrillation: Findings from the RAFFINE registry
CONCLUSIONS: The all-cause mortality, cardiovascular mortality, and incidence of major bleeding events were higher in the warfarin group than in the DOAC group. After adjustment, warfarin use was not associated with an increase in these events. Off-label dosing of DOACs is not rare and is not associated with reduced effectiveness. The impact of off-label dosing of each DOAC on clinical events should be assessed using a larger population.PMID:35346556 | DOI:10.1016/j.jjcc.2022.03.006
Source: Journal of Cardiology - March 29, 2022 Category: Cardiology Authors: Sakiko Miyazaki Katsumi Miyauchi Hidemori Hayashi Kazuo Yamashiro Ryota Tanaka Yuji Nishizaki Shuko Nojiri Satoru Suwa Masataka Sumiyoshi Yuji Nakazato Takao Urabe Nobutaka Hattori Tohru Minamino Hiroyuki Daida Source Type: research

Impact of atrial fibrillation and the clinical outcomes in patients with acute myocardial infarction from the K-ACTIVE registry
CONCLUSION: In Japanese AMI patients, AF was often observed and was associated with worse MACE but not worse bleeding.PMID:35216889 | DOI:10.1016/j.jjcc.2022.02.007
Source: Journal of Cardiology - February 26, 2022 Category: Cardiology Authors: Hiroyoshi Mori Kazuki Fukui Atsuo Maeda Yoshihiro Akashi Junya Ako Yuji Ikari Toshiaki Ebina Kouichi Tamura Atsuo Namiki Ichiro Michishita Kazuo Kimura Hiroshi Suzuki Source Type: research

Initial practice of left atrial appendage closure device in Japan; single-center experience
CONCLUSIONS: In this initial Japanese experience, LAAC therapy for high bleeding risk patients with NVAF seems feasible. Optimal antithrombotic regimens are warranted for better clinical outcomes.PMID:35094892 | DOI:10.1016/j.jjcc.2022.01.004
Source: Journal of Cardiology - January 31, 2022 Category: Cardiology Authors: Masato Fukunaga Akihiro Isotani Shinichi Shirai Naoto Murakami Miho Nakamura Takashi Morinaga Kenichi Ishizu Kazuki Kitano Tatsuhiro Kataoka Masaomi Hayashi Kenichi Hiroshima Kenji Ando Source Type: research

Pages: 1  2  3  4  5